NEW YORK (GenomeWeb) – Rosetta Genomics today announced that its sales partner Admera Health has received approval from the New Jersey Department of Health (NJDH) for the OncoGxSelect panel for clinical use.

Admera's next-generation sequencing-based oncology panel looks at five genes associated with lung cancer. The test detects point mutations, small indels, and gene fusions in KRAS, BRAF, EGFR, ROS1, and ALK to provide clinically actionable results. OncoGxSelect is performed on formalin-fixed, paraffin-embedded tissue samples.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.